Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: NASDAQ GS
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

Rigel Pharmaceuticals Inc

+ Add to Watchlist

RIGL:US

4.0900 USD 0.0800 1.92%

As of 20:10:00 ET on 04/17/2015.

Snapshot for Rigel Pharmaceuticals Inc (RIGL)

Open: 4.1500 Day's Range: 4.0400 - 4.2500 Volume: 491,786
Previous Close: 4.1700 52wk Range: 1.5600 - 4.2500 1-Yr Rtn: +27.81%

Stock Chart for RIGL

No chart data available.
  • RIGL:US 4.0900
  • 1D
  • 1M
  • 1Y
4.1700
Interactive RIGL Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for RIGL

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) -
Relative P/E vs. SPX -
Earnings Per Share (USD) (ttm) -1.0341
Est. EPS (USD) (12/2015) -0.7620
Est. PEG Ratio -
Market Cap (M USD) 360.12
Shares Outstanding (M) 88.05
30 Day Average Volume 834,949
Price/Book (mrq) 2.8078
Price/Sale (ttm) 43.5240
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 05/07/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for RIGL

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for RIGL

Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. The Company's research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms.

Raul R RodriguezChief Executive OfficerRyan D MaynardExec VP/CFO
Elliott B GrossbardExec VP/Chief Medical OfficerDonald G PayanExec VP/Pres:Discovery
More Company Profile & Key Executives for RIGL

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil